P/E ratio for Amarin Corporation (AMRN)
P/E ratio as of May 2024 (TTM): -7.20
According to Amarin Corporation 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.20258. At the end of 2022 the company had a P/E ratio of -4.52.
P/E ratio history for Amarin Corporation from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -4.52 | -103.47% |
| 2021 | 130 | -259.77% |
| 2020 | -81.5 | -73.39% |
| 2019 | -306 | 777.67% |
| 2018 | -34.9 | 117.57% |
| 2017 | -16.0 | 113.52% |
| 2016 | -7.51 | 229.9% |
| 2015 | -2.28 | -25.65% |
| 2014 | -3.06 | 60.12% |
| 2013 | -1.91 | -70.21% |
| 2012 | -6.42 | -322.88% |
| 2011 | 2.88 | -157.97% |
| 2010 | -4.97 | |
| 2007 | -18.6 | -97.96% |
| 2006 | -912 | 34100% |
| 2005 | -2.67 | -164.16% |
| 2004 | 4.16 | -555.44% |
| 2003 | -0.9126 | -11.17% |
| 2002 | -1.03 | -101.06% |
| 2001 | 97.0 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 AbbVie ABBV | 44.2 | -713.50% | 🇺🇸 USA |
 AstraZeneca AZN | 38.2 | -630.74% | 🇬🇧 UK |
 GlaxoSmithKline GSK | 11.8 | -264.35% | 🇬🇧 UK |
 Alkermes ALKS | 18.9 | -362.09% | 🇮🇪 Ireland |
 Teva Pharmaceutical Industries TEVA | -7.03 | -2.47% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.